Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

19 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Copaxone Articles

Net Profits Up 11% For Teva In 1995

11 March 1996

Teva's Copaxone In USA

11 March 1996

Israel's Teva Bidding For World Generics Leadership

12 February 1996

Teva / Hoechst Marion Roussel Copaxone collab

15 January 1996

Biogen's Interferon Beta Nears US Approval

4 December 1995

Improved Third Quarter For Teva Pharmaceutical

20 November 1995

Teva: Copaxone trials news

13 November 1995

Teva Makes $26M Bid For Majority Stake In Biogal

13 November 1995

MS: Hope, Expectations, And Disappointments

23 October 1995

More Israeli Court Action Over MS Drug

11 September 1995

Teva's Copaxone Disappointment

4 September 1995

Disappointing Second Quarter From Teva

14 August 1995

Teva Pharmaceutical: Copaxone

26 June 1995

Israeli GSF "Must Supply Betaseron To MS Patient"

5 June 1995

Biogen Files For Avonex MS Drug In USA

29 May 1995

Biogen Files For Avonex MS Drug In USA

29 May 1995

FDA: Problems With Accepting EMEA Data

22 May 1995

MMD/Teva Agreement

20 March 1995

Teva Moves To Cope With Increased Competition

20 March 1995

MMD To Market Teva's Copaxone

6 February 1995

Teva Copaxon Unit

30 January 1995

...And Israel's Teva Recommended

2 January 1995

World Immunology, Rheumatology Markets

28 November 1994

Teva Pharma's Net Income Up 25% For 3rd Qtr

28 November 1994

Phase III Results For Copolymer 1 Disappointing

17 October 1994

Teva To File COP-1 NDA In Late 1994/Early 1995

1 August 1994

Teva profit falls 57% on acquisition charges

Showing 201-227 of 227 articles

Go to beginningPrevious
  • 1
  • 2
  • 3
NextGo to end
  • Hot Topics
  • Most Read
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
  • Additional indications in Japan for Roche's Avastin and Astellas' Prograf
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
  • Additional indications in Japan for Roche's Avastin and Astellas' Prograf
  • US Supreme Court says patent settlement can "sometimes" be illegal

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS